Results 61 to 70 of about 10,998 (173)

Daunorubicin‐45 Vs. Daunorubicin‐60 for Induction in Intermediate‐Age Patients of AML: Results From a Randomized Trial

Cancer Science, Volume 117, Issue 6, Page 1690-1700, June 2026.
Daunorubicin dose escalation from 45 to 60 mg/m2 provides no clinical benefit for AML patients aged 55–65. A dose of 45 mg/m2 should remain the preferred regimen for this population. ABSTRACT Daunorubicin dose optimization remains crucial for AML treatment.
Chunlin Zhou, Le Li, Yan Li, Kaiqi Liu, Yuntao Liu, Dong Lin, Benfa Gong, Guangji Zhang, Xiaoyuan Gong, Qiuyun Fang, Bingcheng Liu, Shaowei Qiu, Ying Wang, Hui Wei, Yingchang Mi, Jianxiang Wang   +15 more
wiley   +1 more source

Significance of Myelodysplasia‐Related Mutations and the Genetic Landscape of Acute Leukemias of Ambiguous Lineage

International Journal of Laboratory Hematology, Volume 48, Issue 3, Page 512-520, June 2026.
ABSTRACT The recent fifth edition WHO classification and ICC classification systems have moved further toward genetically defined classifications of acute leukemias. Both now recognize myelodysplasia‐related (MR) mutations as defining of MDS‐related AML (AML‐MR).
Timothy J. Kirtek, Olga K. Weinberg
wiley   +1 more source

Common Hematologic Emergencies—Acute Promyelocytic Leukemia and Microangiopathic Hemolytic Anemias—A Pivotal Role of Clinical Laboratory

International Journal of Laboratory Hematology, Volume 48, Issue 3, Page 521-530, June 2026.
ABSTRACT Hematologic emergencies are urgent health conditions which result in significant mortality and morbidity unless timely therapeutic measures are taken. Therapeutic success depends on their timely and accurate recognition by hematology laboratory services.
Ganna Shestakova, Nicolas Ulrich Edgar, Anton V. Rets   +2 more
wiley   +1 more source

SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts

, 2015
Refractory anemia with ring sideroblasts (RARS) is a myelodysplastic syndrome (MDS) characterized by isolated erythroid dysplasia and 15% or more bone marrow ring sideroblasts.
Rosenquist, Richard Brandell,, Jansson, Monika, Ljungström, Viktor,, Kallenbach, Klaus, Elena, Chiara, Boveri, Emanuela, Lindberg, Eva Hellstrom, Galli, Anna, Conte, Simona, Papaemmanuil, Elli, Della Porta, Matteo G., Travaglino, Erica, Pietra, Daniela, Campbell, Peter J., Walldin, Gunilla, Cazzola, Mario, Raaschou-Jensen, Klas, Malcovati, Luca, Ambaglio, Ilaria, Jadersten, Martin, Invernizzi, Rosangela, Karimi, Mohsen   +21 more
core   +2 more sources

The impact of SF3B1 mutations in CLL on the DNA-damage response

Leukemia, 2014
Mutations or deletions in TP53 or ATM are well-known determinants of poor prognosis in chronic lymphocytic leukemia (CLL), but only account for approximately 40% of chemo-resistant patients. Genome-wide sequencing has uncovered novel mutations in the splicing factor sf3b1, that were in part associated with ATM aberrations, suggesting functional synergy.
Te Raa, G D, Derks, I A M, Navrkalova, V, Skowronska, A, Moerland, P D, van Laar, J, Oldreive, C, Monsuur, H, Trbusek, M, Malcikova, J, Lodén, M, Geisler, C H, Hüllein, J, Jethwa, A, Zenz, T, Pospisilova, S, Stankovic, T, van Oers, M H J, Kater, A P, Eldering, E   +19 more
openaire   +4 more sources

The splicing factor Sf3b1 regulates erythroid maturation and proliferation via TGFβ signaling in zebrafish

, 2019
: The spliceosomal component Splicing Factor 3B, subunit 1 (SF3B1) is one of the most prevalently mutated factors in the bone marrow failure disorder myelodysplastic syndrome.
Rosannah C. Cameron, Sara Nik, Ellen Fraint, Adriana De La Garza, Varun Gupta, Teresa V. Bowman   +5 more
core   +1 more source

SF3B1-mutant models of RNA mis-splicing uncover UBA1 as a therapeutic target in myelodysplastic neoplasms

Myelodysplastic syndromes with somatic mutations in the splicing factor SF3B1 gene (MDS-SF3B1) result in RNA mis-splicing, erythroid dysplasia and ultimately refractory anemia.
Elli Papaemmanuil (6499196), Nikolas Herold (18664402), Dimitris Kanellis (18680989), Jonas Thier (22135540), Sophia Hofmann (19569301), Eirini P Papapetrou (21670556), Vanessa Lundin (224979), Ingrid Lilienthal (481336), Pedro L Moura (22135561), Indira Barbosa (22135552), Katharina M Kirchhof (22135543), Teresa Mortera-Blanco (22135549), André G Deslauriers (22135558), Eva Hellström-Lindberg (89573), Ann-Charlotte Björklund (22135555), Jiri Bartek (138045), Gabriele Todisco (22135546)   +16 more
core  

SF3B1: hotspot mutazionale nei prolattinomi [PDF]

L'Endocrinologo, 2021
Giovanna Mantovani, Federica Mangili
openaire   +1 more source

Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts

, 2014
The presence of somatic mutations in splicing factor 3b subunit 1 (SF3B1) in patients with Myelodysplastic syndromes with ring sideroblasts (MDS-RS) highlights the importance of the RNA-splicing machinery in MDS.
Ali Tabarroki, Reda Mahfouz, Visconte, Valeria, Li Zhang, Mikkael A Sekeres, Barnard, John, Haruhiko Koseki, Hasrouni, Edy, Yvonne Parker, Kyoichi Isono, Mahfouz, Reda, Isono, Kyoichi, Edy Hasrouni, Ramon V Tiu, Saunthararajah, Yogen, Sekeres, Mikkael A, Heesun J Rogers, Zhang, Li, John Barnard, Valeria Visconte, Lindner, Daniel, Tabarroki, Ali, Rogers, Heesun J, Yogen Saunthararajah, Daniel Lindner, Koseki, Haruhiko, Parker, Yvonne, Tiu, Ramon V   +27 more
core   +1 more source

Abstract LB-100: Potential role of the splicing factor SF3B1 in epigenetic regulation

, 2017
Driver mutations in splicing factors have been reported in multiple cancer types and SF3B1 is among the most frequently mutated splicing factors. The mechanism(s) of transformation associated with these mutations remain incompletely understood.
Jozef Madzo, Jean-Pierre Issa, Yasuyuki Okamoto, Jaroslav Jelinek, Sandra Deliard   +4 more
core   +1 more source